In older or frail adults >65 years of age with CNS lymphoma who completed high-dose methotrexate containing regimens, would you consider maintenance therapy with monthly temozolomide +/- rituximab or ibrutinib?
Given the emerging data on success of CAR-T cell therapy, would you consider cellular therapy as a potential alternative treatment for relapse in this patient population?